

---

**CORRIGENDUM**

## Targeting MET in cancer: rationale and progress

*Ermanno Gherardi, Walter Birchmeier, Carmen Birchmeier and George Vande Woude*

*Nature Reviews Cancer* **12**, 89–103 (2012)

In the legend to Figure 6c, the distribution according to therapeutic strategy (monotherapy versus combined therapy) involving HGF/SF–MET monotherapies should have read 44%.